论文部分内容阅读
目的:为了初步研究大剂量尿激酶静脉溶栓治疗急性脑梗死的效果及安全性。方法:将急性脑梗死患者随机分为溶栓组及对照组,溶栓组(32例)予尿激酶100万～150万u治疗;对照组(30例)用清栓酶治疗,分别观察疗效。结果:治愈显效率溶栓组高于对照组(P<0.05),分别为53.1%、23.3%;早期疗效(治疗6小时内)比较有差异(P<0.05);溶栓组发病各时间段的总显效率亦优于对照组。结论:尿激酶静脉溶栓治疗安全有效,早期疗效显著、迅速,治疗越早越好。
OBJECTIVE: To study the efficacy and safety of intravenous thrombolysis with high-dose urokinase in the treatment of acute cerebral infarction. Methods: Acute cerebral infarction patients were randomly divided into thrombolytic group and control group, thrombolytic group (32 cases) to urokinase 1 million to 1.5 million u treatment; control group (30 cases) treated with clear thrombin, were observed efficacy . Results: The effective rate of thrombolytic therapy in the thrombolytic group was significantly higher than that in the control group (53.1%, 23.3%, respectively). The early treatment effect (within 6 hours) was significantly different (P <0.05) The total effective rate is also better than the control group. Conclusion: The urokinase intravenous thrombolysis is safe and effective. The early curative effect is obvious and rapid, and the earlier the treatment, the better.